Minoryx Therapeutics receives approval to initiate phase 2 study in Friedreich’s Ataxia

The phase 2 trial, FRAMES, is expected to start patient enrollment in the coming weeks in the Hospital La Paz (Madrid), lead by Dr. Francisco Javier Rodríguez de Rivera. The company is also working to open additional sites at medical institutions in Belgium, Germany and France. The upcoming trial is designed to be double-blind and placebo-controlled with the aim of assessing the efficacy and safety of MIN-102 in Friedreich’s Ataxia patients.  For more information please find the press release here.  

Read more

Ncardia Launches iPSC-Based Phenotypic Screening Service to Bring Human Disease Biology Earlier into Drug Discovery and Development

Ncardia, a leading provider of human iPSCderived cell-based assays and services for drug discovery and development, announced the launch of their DiscoverHIT drug screening platform. The new service enables researchers to access human disease-relevant biology earlier in the drug discovery process with the goal of bringing better medicines to patients faster.  For more infomration please find the press release here.

Read more